Sophia Genetics SA (SOPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sophia Genetics SA (SOPH) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.79 Million) by net assets ($60.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SOPH market cap for the company's overall valuation and market capitalisation.
Sophia Genetics SA - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sophia Genetics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sophia Genetics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sophia Genetics SA ranked by their cash flow conversion efficiency. See SOPH cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
0.040x |
|
S.P.I Landscape Design Co. Ltd.
SHE:300844
|
N/A |
|
Denny’s Corp
NASDAQ:DENN
|
-0.489x |
|
Radium Life Tech Co Ltd
TW:2547
|
0.025x |
|
Trifork Holding AG
CO:TRIFOR
|
0.035x |
|
Dongnan Electronics Co. Ltd. A
SHE:301359
|
N/A |
|
Guangdong Tianhe Agricultural Means
SHE:002999
|
-0.233x |
|
Liuzhou Chemical Industry Co Ltd
SHG:600423
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Sophia Genetics SA (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sophia Genetics SA from 2019 to 2024. View Sophia Genetics SA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $96.49 Million | $-42.82 Million | -0.444x | -38.36% |
| 2023-12-31 | $151.44 Million | $-48.58 Million | -0.321x | +8.42% |
| 2022-12-31 | $200.13 Million | $-70.09 Million | -0.350x | -66.48% |
| 2021-12-31 | $275.40 Million | $-57.94 Million | -0.210x | +33.36% |
| 2020-12-31 | $100.51 Million | $-31.73 Million | -0.316x | +77.82% |
| 2019-12-31 | $22.25 Million | $-31.68 Million | -1.424x | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more